Home - News ( United States | United Kingdom | Italy | Germany ) - Football scores

Showing content from https://pubmed.ncbi.nlm.nih.gov/22816528/ below:

The implications of age and comorbidity on survival following epithelial ovarian cancer: summary and results from a Centers for Disease Control and Prevention study

Affiliations

• ¹ Amgen Inc. , One Amgen Center Drive, Thousand Oaks, CA 91320, USA. comalley@amgen.com

• PMID: 22816528
• DOI: 10.1089/jwh.2012.3781

Item in Clipboard

Cynthia D O'Malley et al. J Womens Health (Larchmt). 2012 Sep.

• ¹ Amgen Inc. , One Amgen Center Drive, Thousand Oaks, CA 91320, USA. comalley@amgen.com

• PMID: 22816528
• DOI: 10.1089/jwh.2012.3781

Item in Clipboard

Background: Advances in treatment have improved ovarian cancer survival for most women, although less for the elderly. We report on this disparity and add further evidence about the relationship among age, comorbidity, and survival after ovarian cancer.

Methods: To examine age and comorbidity, Centers for Disease Control and Prevention (CDC)-funded cancer registries examined 2367 women residing in New York and Northern California diagnosed with epithelial ovarian cancer (1998-2000). Subjects were identified through tumor registries, treatment data were supplemented with physician survey, and comorbidity was identified through hospital discharge database linkages. Proportional hazards modeling was used to estimate the risk of death by age and comorbidity, adjusting for clinical and sociodemographic factors.

Results: Crude survival at 1 year and 3 years was 71.9% and 50.1%, respectively. Within stage, age-specific survival rates were lower in the oldest groups, particularly for those with advanced disease. For age 75+, 3-year survival was 13% vs. 50% in those <35 (stage IV). For all stages, women without comorbidity had higher survival rates than those with comorbidity. Older age and comorbidity were both associated with advanced stage and less aggressive treatment. The adjusted risk of death was 40%, and it was 80% higher for the 65-74 and 75+ groups, respectively, compared to women 35-64 (p<0.00). Comorbidity increased the risk of death by 40% (p<0.00).

Conclusions: This study confirmed the independent adverse effects of age and comorbidity on survival following ovarian cancer. As the population ages, the co-occurrence of ovarian cancer and comorbidity will increase. Further work identifying critical conditions that impact survival could potentially inform complex treatment decisions.

PubMed Disclaimer

• Survival of Australian women with invasive epithelial ovarian cancer: a population-based study.

  Anuradha S, Webb PM, Blomfield P, Brand AH, Friedlander M, Leung Y, Obermair A, Oehler MK, Quinn M, Steer C, Jordan SJ. Anuradha S, et al. Med J Aust. 2014 Sep 1;201(5):283-8. doi: 10.5694/mja14.00132. Med J Aust. 2014. PMID: 25163381

• Ovarian cancer outcomes: Predictors of early death.

  Urban RR, He H, Alfonso R, Hardesty MM, Gray HJ, Goff BA. Urban RR, et al. Gynecol Oncol. 2016 Mar;140(3):474-80. doi: 10.1016/j.ygyno.2015.12.021. Epub 2015 Dec 29. Gynecol Oncol. 2016. PMID: 26743531

• Statin treatment is associated with survival in a nationally representative population of elderly women with epithelial ovarian cancer.

  Vogel TJ, Goodman MT, Li AJ, Jeon CY. Vogel TJ, et al. Gynecol Oncol. 2017 Aug;146(2):340-345. doi: 10.1016/j.ygyno.2017.05.009. Epub 2017 Jun 7. Gynecol Oncol. 2017. PMID: 28596017

• Feto-maternal outcomes of pregnancy complicated by epithelial ovarian cancer: a systematic review of literature.

  Blake EA, Kodama M, Yunokawa M, Ross MS, Ueda Y, Grubbs BH, Matsuo K. Blake EA, et al. Eur J Obstet Gynecol Reprod Biol. 2015 Mar;186:97-105. doi: 10.1016/j.ejogrb.2015.01.010. Epub 2015 Jan 23. Eur J Obstet Gynecol Reprod Biol. 2015. PMID: 25668134 Review.

• Epidemiology of epithelial ovarian cancer.

  Webb PM, Jordan SJ. Webb PM, et al. Best Pract Res Clin Obstet Gynaecol. 2017 May;41:3-14. doi: 10.1016/j.bpobgyn.2016.08.006. Epub 2016 Oct 3. Best Pract Res Clin Obstet Gynaecol. 2017. PMID: 27743768 Review.

• Considerations in the surgical management of ovarian cancer in the elderly.

  Langstraat C, Cliby WA. Langstraat C, et al. Curr Treat Options Oncol. 2013 Mar;14(1):12-21. doi: 10.1007/s11864-012-0216-2. Curr Treat Options Oncol. 2013. PMID: 23197271 Review.

• Impact of liver cirrhosis due to chronic hepatitis C viral infection on the outcome of ovarian cancer: a prospective study.

  Refky B, Kotb S, Fady T, Marwan A, Abd El-Khalek D, Elnahas W, Hafez MT, Malik E, Soliman AA. Refky B, et al. BMC Cancer. 2015 Oct 21;15:754. doi: 10.1186/s12885-015-1805-9. BMC Cancer. 2015. PMID: 26486859 Free PMC article.

• Disparities in ovarian cancer survival in the United States (2001-2009): Findings from the CONCORD-2 study.

  Stewart SL, Harewood R, Matz M, Rim SH, Sabatino SA, Ward KC, Weir HK. Stewart SL, et al. Cancer. 2017 Dec 15;123 Suppl 24(Suppl 24):5138-5159. doi: 10.1002/cncr.31027. Cancer. 2017. PMID: 29205312 Free PMC article.

• Impact of Rurality on Stage IV Ovarian Cancer at Diagnosis: A Midwest Cancer Registry Cohort Study.

  Weeks KS, Lynch CF, West M, McDonald M, Carnahan R, Stewart SL; Ovarian Cancer Treatment Study; Charlton M. Weeks KS, et al. J Rural Health. 2020 Sep;36(4):468-475. doi: 10.1111/jrh.12419. Epub 2020 Feb 20. J Rural Health. 2020. PMID: 32077162 Free PMC article.

• An evaluation of cancer survivorship activities across national comprehensive cancer control programs.

  Underwood JM, Lakhani N, Rohan E, Moore A, Stewart SL. Underwood JM, et al. J Cancer Surviv. 2015 Sep;9(3):554-9. doi: 10.1007/s11764-015-0432-4. Epub 2015 Mar 3. J Cancer Surviv. 2015. PMID: 25732543 Free PMC article.

RetroSearch is an open source project built by @garambo | Open a GitHub Issue

Search and Browse the WWW like it's 1997 | Search results from DuckDuckGo

HTML: 3.2 | Encoding: UTF-8 | Version: 0.7.3